Kala Pharmaceuticals, Inc., a leading developer of innovative nanotechnology-based ophthalmic products leveraging the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of a Phase 2 clinical trial (KPI-121-C-004) to evaluate KP-121, the company’s loteprednol etabonate MPP (“LE-MPP”) drug product, in patients with intraretinal or subretinal fluid secondary to retinal vein occlusion (RVO) or diabetic macular edema (DME).
A fast and cost-effective genetic test to determine the correct dosage of blood thinning drugs for the treatment of stroke, heart problems and deep vein thrombosis has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN). Using gold nanoprobes, this new technology offers personalized healthcare based on the genetic profile of the patients.
Today, Providence Health & Services announced that Dr. Patrick Soon-Shiong, a physician, surgeon and scientist known globally for applying collaborative science and technology to improve the health of patients battling life-threatening disease, will serve as the health care system's new global director for cancer services and bioinformatics.
Intracerebral hemorrhage is a type of stroke that affects two million people worldwide each year. Despite its seriousness, no effective treatment has yet been developed. But if a recent study in the journal Nanomedicine is right, good news for doctors and patients might one day arrive in a very small package: namely, a “peptide nanofiber scaffold.”
If you thought that the most impressive news in shrinking technology these days was smart watches, think again. Scientists are quietly toiling in their laboratories to create robots that are only nanometers – billionths of a meter – in length, small enough to maneuver inside the human body and possibly inside human cells.
Imbed Biosciences, Inc, a medical device company developing advanced materials for wound healing and surgical applications, announced today that it has been awarded a $1.5M competitive Small Business Innovation Research (SBIR) Phase II grant from National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of National Institutes of Health (NIH).
Nanomaterials and Nanotechnology journal has received its first Journal Impact Factor of 0.949 as of July 29th, 2014. Up to this date, all journal's Volumes have been indexed in SCIE and Current Contents databases, as well as in Scopus.
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading.
Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases.
NanoViricides, Inc. celebrated the grand opening of its new R&D and cGMP pilot manufacturing facility with Congressman Jim Himes as the Chief Guest yesterday, July 21.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.